Repotrectinib for lung cancer with brain metastasis
Treatments studied
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This trial tests a targeted pill called repotrectinib for people with a specific type of lung cancer (ROS1-positive non-small cell lung cancer) that has spread to the brain. The drug aims to shrink brain tumors and control the cancer, especially when brain-focused treatments like surgery or radiation are not needed right away.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have non-small cell lung cancer with a ROS1 gene change (your doctor will have tested for this)
- You have brain metastasis (possibly with symptoms), but you don't need urgent brain surgery or radiation
- You have at least one brain lesion that is 10 mm or larger, as seen on an MRI
- You are able to swallow capsules whole
- You have adequate organ function as determined by blood tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted pill (limertinib) combined with radiation therapy for people with a specific type of lung cancer (EGFR-mutant) that has spread to the brain. The goal is to see if this combination can shrink tumors and improve outcomes.
This study looks at how well a targeted therapy works for people with advanced non-small cell lung cancer that has a specific genetic change called ROS1. It aims to see if this treatment can help control the cancer and improve outcomes.
This trial tests a combination of focused radiation (stereotactic radiosurgery) and an oral targeted therapy called anlotinib for people with non-small cell lung cancer that has spread to the brain. It may offer a way to control brain metastases without more invasive procedures.
This Phase 3 study tests whether giving brain radiation early or later, along with almonertinib (a targeted pill), works better for people with EGFR-mutated non-small cell lung cancer that has a small number of brain metastases. It aims to control brain disease while checking safety and effectiveness in a carefully selected group.
This trial tests a combination of three drugs (datopotamab deruxtecan, carboplatin, and pembrolizumab) for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread to the brain and has not been treated before. The goal is to see if this combination can shrink tumors in the brain and elsewhere.
This trial tests a combination of two targeted pills (furmonertinib and anlotinib) as a first treatment for people with advanced EGFR-mutant non-small cell lung cancer that has spread to the brain. It aims to see if this combination works better than the standard approach for controlling the cancer.
Hear when a new Brain Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.